

proBNP II

cobas®

REF	Σ	SYSTEM
04842464 190	100	MODULAR ANALYTICS E170 cobas e 411 cobas e 601 cobas e 602

English

System information

For **cobas e 411** analyzer: test number 271
For MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers: Application Code Number 091

Intended use

Immunoassay for the in vitro quantitative determination of N-terminal pro B-type natriuretic peptide in human serum and plasma. This assay is indicated as an aid in the diagnosis of individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction.^{1,2,3,4,5,6,7,8}

The test also aids in the assessment of heart failure severity in patients diagnosed with congestive heart failure.^{9,10}

This assay is further indicated for the risk stratification of patients with acute coronary syndrome^{11,12,13,14,15} and congestive heart failure, and it can also be used for monitoring the treatment in patients with left ventricular dysfunction.^{1,2,16,17,18,19,20}

The **electrochemiluminescence immunoassay** "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.

Summary

Heart failure is a clinical syndrome characterized by systemic perfusion inadequate to meet the body's metabolic demands as a result of a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress.^{1,2,3} Left ventricular dysfunction can be one of the functional precursors of heart failure.^{1,2}

Heart failure is a progressive disease where in both hospitalized and ambulatory patients, most deaths are due to cardiovascular causes, mainly sudden death and worsening HF.^{1,2}

The typical terminology used to describe HF is based on measurement of the Left Ventricular Ejection Fraction (LVEF). According to latest ESC guidelines, HF comprises a wide range of patients, from those with normal LVEF [typically considered as $\geq 50\%$; HF with preserved EF (HFpEF)] to those with reduced LVEF [typically considered as $< 40\%$; HF with reduced EF (HFrEF)]. Patients with an LVEF in the range of 40-49% represent a 'grey area', which is now defined as HF with midrange EF (HFmrEF).^{1,2,3} Clinical information and imaging procedures are used to confirm the diagnosis of heart failure.^{1,2,3}

The significance of natriuretic peptides in the control of cardiovascular system function has been demonstrated. The following natriuretic peptides have been described: atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).^{21,22}

ANP and BNP, as antagonists of the renin-angiotensin-aldosterone system, influence by means of their natriuretic and diuretic properties, the electrolyte and fluid balance in an organism.^{23,24,25} In subjects with left ventricular dysfunction, serum and plasma concentrations of BNP increase, as does the concentration of the putatively inactive amino-terminal fragment, NT-proBNP. ProBNP, comprising 108 amino acids, is secreted mainly by the ventricle and, in this process, is cleaved into physiologically active BNP (77-108) and the N-terminal fragment NT-proBNP (1-76).^{22,23}

Several studies have demonstrated the significant role of natriuretic peptide testing, including NT-proBNP, in heart failure management from diagnosis to monitoring, leading to the recommendation to use them in clinical practice by major international guidelines with often highest level of evidence and recommendation.^{1,2}

Based on the symptoms, the severity of heart failure is classified in stages (New York Heart Association classification [NYHA] I-IV). When patients are grouped according to their NYHA classification, NT-proBNP levels increase with increasing class numbers and reflect the severity of cardiac impairment.^{9,10}

Heart failure symptoms are often non-specific and do not help to discriminate between heart failure and other conditions, such as (non-

cardiogenic) pulmonary edema, chronic obstructive pulmonary disease (COPD), pneumonia or sepsis.^{1,2}

The European Society of Cardiology Heart Failure Guidelines recommends natriuretic peptides, including NT-proBNP, as an initial diagnostic test.¹ Patients with NT-proBNP below the recommended NT-proBNP cutoffs for non-acute and acute onsets are unlikely to have HF, and therefore do not require echocardiography - and elevated NT-proBNP help to identify patients who require further cardiac investigation.¹ When used with the recommended cutoff, the Elecsys proBNP assay yields negative predictive values ranging from 97% to 100% depending on age and gender.¹⁰

The test is also useful in the early stages of heart failure, where symptoms may be transient rather than present all the time.³ The high sensitivity of NT-proBNP allows also the detection of mild forms of cardiac dysfunction in asymptomatic patients with structural heart disease.^{4,5,6,7,8}

NT-proBNP can also be used for prognostic applications in patients with acute coronary syndrome. The GUSTO IV study, with more than 6800 patients, showed that NT-proBNP was the strongest independent predictor of one year mortality in patients with acute coronary syndrome.¹⁵

In patients hospitalized for acute decompensated heart failure, pre-discharge measurement of natriuretic peptides is useful to categorize patient's risk at discharge.^{1,16} Changes in NT-proBNP levels during hospitalization demonstrated to be a strong predictor of outcomes.^{16,26,27,28,29} A decrease in NT-proBNP values of $\geq 30\%$ has shown to be correlated with favorable outcome, while an increase in NT-proBNP values $> 30\%$ was correlated with 6.6 times higher risk of rehospitalization or death in 6 months.¹⁶

In chronic heart failure, serial measurement of NT-proBNP concentration can be used to monitor the disease progression, to predict outcomes and evaluate the success of treatment.^{1,2,17,18,20,30,31}

Elevated NT-proBNP values are strongly predictive of adverse outcomes and rising values identify a risk, while significant lowering of NT-proBNP denotes improved outcomes and better prognosis.^{1,2,17,32}

When NT-proBNP levels change during treatment of chronic heart failure, decrease over the course of the disease correlated with improved clinical outcomes.^{1,2,18,20} This interpretation of NT-proBNP results remains unchanged when using the new drug class Angiotensin receptor-neprilysin inhibitor^{1,2} (ARNI, e.g. sacubitril-valsartan): In contrast to BNP, NT-proBNP degradation is not inhibited by the drug so that NT-proBNP results are not increased by the mode of action of the drug.^{19,33,34} In patients treated with sacubitril-valsartan, rapid and sustained reduction of NT-proBNP levels has been observed, reflecting reduced wall stress³³ and benefits of the drug correlating with a lower rate of cardiovascular death and heart failure hospitalization.²⁰

NT-proBNP can be used before non-cardiac surgery to evaluate patients' perioperative cardiac risk.³⁵

In addition NT-proBNP can be used to identify patients at higher risk of cardiotoxicity which can lead to heart failure and may be helpful in monitoring the use and dosing of cardiotoxic tumor drugs^{1,36,37} or interventions causing fluid retention or volume overload (e.g. COX-2 inhibitors, nonsteroidal anti-inflammatory drugs).^{38,39,40,41,42,43,44,45}

In meta-analysis including 95617 patients without history of cardiovascular disease, NT-proBNP concentration strongly predicted first-onset heart failure and augmented chronic heart disease and stroke prediction, suggesting that NT-proBNP could serve as a biomarker in new therapeutic approaches that integrate heart failure into cardiovascular disease primary prevention.⁴⁶

The Elecsys proBNP II assay contains two monoclonal antibodies which recognize epitopes located in the N-terminal part (1-76) of proBNP (1-108).

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

proBNP II



- 1st incubation: Antigen in the sample (15 µL), a biotinylated monoclonal NT-proBNP-specific antibody, and a monoclonal NT-proBNP-specific antibody labeled with a ruthenium complex^{a)} form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode or e-barcode.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The reagent rackpack is labeled as PRO-BNP II.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL:
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-NT-proBNP-Ab~biotin (gray cap), 1 bottle, 9 mL:
Biotinylated monoclonal anti-NT-proBNP antibody (mouse)
1.1 µg/mL; phosphate buffer 40 mmol/L, pH 5.8; preservative.
- R2 Anti-NT-proBNP-Ab~Ru(bpy)₃²⁺ (black cap), 1 bottle, 9 mL:
Monoclonal anti-NT-proBNP antibody (sheep) labeled with ruthenium complex 1.1 µg/mL; phosphate buffer 40 mmol/L, pH 5.8; preservative.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	12 weeks
on the analyzers	8 weeks

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-, NH₄-heparin, K₂-EDTA and K₃-EDTA plasma.

Criterion: Recovery within 90-110 % of serum value or slope
0.9-1.1 + intercept within < ± 2x analytical sensitivity (lower detection limit) + coefficient of correlation > 0.95.

Stable for 3 days at 20-25 °C, 6 days at 2-8 °C, 24 months at -20 °C (± 5 °C).

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all

available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- [REF] 04842472190, proBNP II CalSet, for 4 x 1.0 mL
- [REF] 04917049190, PreciControl Cardiac II, for 4 x 2.0 mL
- [REF] 11732277122, Diluent Universal, 2 x 16 mL sample diluent or [REF] 03183971122, Diluent Universal, 2 x 36 mL sample diluent
- General laboratory equipment
- MODULAR ANALYTICS E170 or **cobas e** analyzer

Accessories for **cobas e** 411 analyzer:

- [REF] 11662988122, ProCell, 6 x 380 mL system buffer
- [REF] 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution
- [REF] 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive
- [REF] 11933159001, Adapter for SysClean
- [REF] 11706802001, AssayCup, 60 x 60 reaction cups
- [REF] 11706799001, AssayTip, 30 x 120 pipette tips
- [REF] 11800507001, Clean-Liner

Accessories for MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 analyzers:

- [REF] 04880340190, ProCell M, 2 x 2 L system buffer
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- [REF] 03004899190, PreClean M, 5 x 600 mL detection cleaning solution
- [REF] 12102137001, AssayTip/AssayCup, 48 magazines x 84 reaction cups or pipette tips, waste bags
- [REF] 03023150001, WasteLiner, waste bags
- [REF] 03027651001, SysClean Adapter M

Accessories for all analyzers:

- [REF] 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers (except for the **cobas e** 602 analyzer).

MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 analyzers: PreClean M solution is necessary.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

Calibration

Traceability: This method has been standardized against the Elecsys proBNP assay ([REF] 03121640122). This in turn is traceable to pure synthetic NT-proBNP (1-76) by weight.

Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 7 days when using the same reagent kit on the analyzer
- as required: e.g. quality control findings outside the defined limits

Quality control

For quality control, use PreciControl Cardiac II.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in pmol/L or pg/mL).

Conversion factors:

$$\text{pmol/L} \times 8.457 = \text{pg/mL}$$

$$\text{pg/mL} \times 0.118 = \text{pmol/L}$$

Limitations - interference

The assay is unaffected by icterus (bilirubin < 428 µmol/L or < 25 mg/dL), hemolysis (Hb < 0.621 mmol/L or < 1.0 g/dL), lipemia (Intralipid < 17.1 mmol/L or < 1500 mg/dL) and biotin (< 123 nmol/L or < 30 ng/mL).

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of 1500 IU/mL.

There is no high-dose hook effect at NT-proBNP concentrations up to 35400 pmol/L (300000 pg/mL).

In vitro tests were performed on 51 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

In extremely rare cases (global incidence: < 1 in 10 million), patients may show discrepant results when tested with the assay kit (values < lower detection limit) due to a NT-proBNP genetic variant.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Limits and ranges

Measuring range

5-35000 pg/mL or 0.6-4130 pmol/L (defined by the lower detection limit and the maximum of the master curve). Values below the lower detection limit are reported as < 5 pg/mL (< 0.6 pmol/L). Values above the measuring range are reported as > 35000 pg/mL (> 4130 pmol/L) or up to 70000 pg/mL (8260 pmol/L) for 2-fold diluted samples.

Lower limits of measurement

Lower detection limit of the test

Lower detection limit: 5 pg/mL (0.6 pmol/L)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying two standard deviations above that of the lowest standard (master calibrator, standard 1 + 2 SD, repeatability study, n = 21).

Dilution

Samples with NT-proBNP concentrations above the measuring range can be diluted with Diluent Universal. The recommended dilution is 1:2 (either automatically by the analyzers or manually). The concentration of the diluted sample must be > 1770 pmol/L or > 15000 pg/mL.

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzers, the software automatically takes the dilution into account when calculating the sample concentration.

Dilutions of up to 1:10 may entail maximum deviations of 25 % from the theoretical value.

Clinical data

Interpretation of NT-proBNP values

With increasing age atherosclerosis and aging processes of the heart (e.g. fibrosis) result in cardiac dysfunction. Development of cardiac dysfunction is individually different and clinically asymptomatic in its early stages.^{47,48} NT-proBNP levels reflect cardiac function or dysfunction respectively. With increasing age elevated levels of NT-proBNP are more frequently found in apparently healthy individuals, thus reflecting the increasing frequency of cardiac dysfunction.

NT-proBNP values need to be interpreted in conjunction with the medical history, clinical findings and other information (e.g. imaging, laboratory findings, accompanying disorders, treatment effects).

Cutoff values

A number of studies support a decision threshold for NT-proBNP of 125 pg/mL. NT-proBNP values < 125 pg/mL exclude cardiac dysfunction with a high level of certainty in patients with symptoms suggestive of heart failure e.g. dyspnea.^{1,3,49,50} NT-proBNP values > 125 pg/mL may indicate cardiac dysfunction and are associated with an increased risk of cardiac complications (myocardial infarction, heart failure, death).

Recommended cutoffs in patients with diagnosed stable chronic heart failure

Patients with stable heart failure (n = 721) were compared to the reference group (n = 2264).

ROC plot analysis at the cutoff value of 125 pg/mL showed a sensitivity of 88 %, a specificity of 92 %, a negative predictive value (NPV), and a positive predictive value (PPV) of 96.7 % and 80.6 %, respectively.

Expected values

NT-proBNP concentrations in the reference group are shown in the following tables. The most appropriate decision threshold apparent from these distributions is 125 pg/mL.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Reference group

The circulating NT-proBNP concentration was determined in samples from 1981 blood donors aged between 18 and 65 as well as 283 elderly patients aged between 50 and 90, both populations without known cardiac risks, symptoms or medical history.

The descriptive statistics for NT-proBNP concentrations (pg/mL) in the reference group are shown in the following table:

All						
Age (years)	N	Mean	SD	Median	95 th percentile	97.5 th percentile
18-44	1323	35.6	30.2	20.4	97.3	115
45-54	408	49.3	63.3	30.7	121	172
55-64	398	72.6	84.4	47.3	198	263
65-74	102	107	85.9	85.1	285	349
≥ 75	33	211	152	174	526	738

proBNP II



All						
Age (years)	N	Mean	SD	Median	95 th percentile	97.5 th percentile
Total	2264	50.3	62.4	27.9	149	196

Males						
Age (years)	N	Mean	SD	Median	95 th percentile	97.5 th percentile
18-44	815	27.7	25.5	20.0	62.9	85.8
45-54	278	39.0	63.6	21.6	83.9	121
55-64	259	57.2	74.5	37.7	161	210
65-74	61	105	87.9	83.9	241	376
≥ 75	13	163	116	151	486	486
Total	1426	39.8	55.3	20.0	113	169

Females						
Age (years)	N	Mean	SD	Median	95 th percentile	97.5 th percentile
18-44	508	48.2	32.8	37.1	116	130
45-54	130	71.5	56.7	55.4	169	249
55-64	139	101	94.0	79.6	247	287
65-74	41	109	83.8	85.2	285	301
≥ 75	20	243	167	191	738	738
Total	838	68.2	69.3	47.8	177	254

In the pediatric population aged between 1 and 18 the following NT-proBNP values were obtained using the Elecsys proBNP assay, [REF] 03121640122:⁵¹

Age (years)	N	NT-proBNP (ng/L)	
		75 th percentile	97.5 th percentile
1-3	13	231	320
4-6	21	113	190
7-9	32	94	145
10	11	73	112
11	69	93	317
12	21	95	186
13	23	114	370
14	18	68	363
15	24	74	217
16	24	85	206
17	24	71	135
18	12	53	115

Correlation of NT-proBNP with NYHA classification in patients diagnosed with CHF

NT-proBNP values (pg/mL) for patients with restricted left ventricular ejection fraction (majority under therapy).

NYHA functional class				
	NYHA I	NYHA II	NYHA III	NYHA IV
N	182	250	234	35
Mean	1016	1666	3029	3465
SD	1951	2035	4600	4453
Median	342	951	1571	1707
5 th percentile	33.0	103	126	148

NYHA functional class				
	NYHA I	NYHA II	NYHA III	NYHA IV
95 th percentile	3410	6567	10449	12188
% > 125 pg/mL	78.6	94.0	95.3	97.1

Patients presenting acute dyspnea - ICON (International Collaborative of NT-proBNP) study¹⁰

NT-proBNP concentrations were determined in samples from 1256 patients presenting with acute shortness of breath to emergency departments at four hospitals. This population included patients with a prior history of hypertension, coronary artery disease, myocardial infarction, heart failure, or pulmonary disease. 720 subjects were found to be suffering from acute exacerbation of heart failure, while the remainder were determined to present dyspnea due to other causes. The descriptive statistics for NT-proBNP concentrations (pg/mL) for both groups are shown in the following table:

ICON Population	Acute dyspnea without acute heart failure			Acute dyspnea with acute heart failure		
	< 50	50-75	> 75	< 50	50-75	> 75
Age (years)						
Mean	163	500	1209	7947	7964	10519
SD	484	1239	2703	9093	12892	15961
Median	42	121	327	5044	3512	5495
5 th percentile	5	10	24	393	416	658
25 th percentile	16	44	139	2257	1608	2154
95 th percentile	104	402	910	9825	9262	11900
97.5 th percentile	778	2101	7916	36201	29089	35183
Min.	1	1	2	196	38	17
Max.	4386	10467	15725	43177	117390	117390
N	150	281	105	33	251	436

Result interpretation in patients presenting acute dyspnea

By using the optimal cutoffs established by the ICON study group and shown in the table below, physicians can increase the specificity and accuracy for diagnosing heart failure in patients presenting acute dyspnea in the emergent setting.

Category	Optimal cut-point pg/mL	Sensitivity %	Specificity %	PPV %	NPV %	Accuracy %
<i>Rule in cut-point</i>						
< 50 years (n = 184)	450	97	93	79	99	94
50-75 years (n = 537)	900	90	82	83	88	85
> 75 years (n = 535)	1800	85	73	92	55	83
<i>Rule out cut-point</i>						
All patients	300	99	60	77	98	83

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a modified protocol (EP5-A) of the CLSI (Clinical and Laboratory

proBNP II



Standards Institute): 6 times daily for 10 days (n = 60); repeatability on MODULAR ANALYTICS E170 analyzer, n = 21. The following results were obtained:

cobas e 411 analyzer					
Sample	Repeatability				
	Mean		SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	
Human serum 1	44.0	5.19	1.84	0.22	4.2
Human serum 2	126	14.9	3.06	0.36	2.4
Human serum 3	2410	284	31.7	3.74	1.3
Human serum 4	33606	3966	922	109	2.7
PC CARDII ^b 1	82.0	9.68	2.11	0.25	2.58
PC CARDII2	2318	274	27.3	3.22	1.18

b) PC CARDII = PreciControl Cardiac II

cobas e 411 analyzer					
Sample	Intermediate precision				
	Mean		SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	
Human serum 1	44.0	5.19	2.02	0.24	4.6
Human serum 2	126	14.9	3.23	0.38	2.6
Human serum 3	2410	284	44.2	5.22	1.8
Human serum 4	33606	3966	1288	152	3.8
PC CARDII1	82.0	9.68	2.27	0.27	2.8
PC CARDII2	2318	274	36.6	4.32	1.6

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers					
Sample	Repeatability				
	Mean		SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	
Human serum 1	64	7.55	1.21	0.14	1.9
Human serum 2	124	14.6	1.82	0.22	1.5
Human serum 3	14142	1669	182	21.5	1.3
PC CARDII1	77.0	9.09	1.41	0.17	1.8
PC CARDII2	2105	248	24.8	2.92	1.2

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers					
Sample	Intermediate precision				
	Mean		SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	
Human serum 1	46	5.43	1.44	0.17	3.1
Human serum 2	125	14.75	3.43	0.40	2.7
Human serum 3	32930	3885	546	64.4	1.7
PC CARDII1	77.0	9.09	2.12	0.25	2.7
PC CARDII2	2170	256	59.4	7.01	2.7

Method comparison

A comparison of the Elecsys proBNP II assay, [REF] 04842464190 (y) with the Elecsys proBNP assay, [REF] 03121640122 (x) using clinical samples gave the following correlations (pg/mL):

Number of samples measured: 2133

Passing/Bablok⁵²

$$y = 0.977x + 1.89$$

Linear regression

$$y = 0.999x - 13.36$$

$$r = 0.946$$

$$r = 0.996$$

The sample concentrations were between approximately 5 and 30022 pg/mL (approximately 0.6 and 3543 pmol/L).

Analytical specificity

The Elecsys proBNP II assay does not show any significant cross reactions with the following substances, tested with NT-proBNP concentrations of approximately 230 pg/mL and 2300 pg/mL (max. tested concentration):

Cross-reactant	Concentration tested
Adrenomedullin	1.0 ng/mL
Aldosterone	0.6 ng/mL
Angiotensin I	0.6 ng/mL
Angiotensin II	0.6 ng/mL
Angiotensin III	1.0 ng/mL
ANP ₂₈	3.1 µg/mL
Arg-vasopressin	1.0 ng/mL
BNP ₃₂	3.5 µg/mL
CNP ₂₂	2.2 µg/mL
Endothelin	20 pg/mL
NT-proANP ₁₋₃₀ (preproANP ₂₆₋₅₅)	3.5 µg/mL
NT-proANP ₃₁₋₆₇ (preproANP ₅₆₋₉₂)	1.0 ng/mL
NT-proANP ₇₉₋₉₈ (preproANP ₁₀₄₋₁₂₃)	1.0 ng/mL
Renin	50 ng/mL
Urodilatin	3.5 µg/mL

Functional sensitivity

50 pg/mL (5.9 pmol/L)

The functional sensitivity is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of 20 %.

References

- 1 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2016;18(8):891-975.
- 2 Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology. Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013 15;128(16):1810-1852.
- 3 Rutten FH, Taylor CJ, Judith R, et al. Practical Guidance on Heart Failure Diagnosis and Management in Primary Care. European Primary Care Cardiovascular Society | Version 22-09-2016. <http://www.epccs.eu/bestanden/b8695636106717584158253-EPCCS-2016-HF-Diagnosis-webversion.pdf>
- 4 Mueller T, Gegenhuber A, Poelz W, et al. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004;341:41-48.
- 5 McGrady M, Reid CM, Shiel L, et al. NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: results of the SCReening Evaluation of the Evolution of New Heart Failure study (SCREEN-HF). Int J of Card 2013;169(2):133-138.
- 6 Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47(2):345-353.
- 7 O'Donoghue M, Chen A, Baggish AL, et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Journ of Card Fail 2005;11(5):9-14.

- 8 Mureddu GF, Tarantini L, Agabiti N, et al. Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from 'PREDICTOR', a population based-study in central Italy European Journal of Heart Failure 2013;15:1102-1112.
- 9 Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol 1997;47(3):287-296.
- 10 Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients The International Collaborative of NT-proBNP Study Euro Heart Journ 2006;27(3):330-337.
- 11 Richards AM, Nicholls GM, Yandle TG, et al. Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin: New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction. Circulation 1998;97:1921-1929.
- 12 Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004;6:327-333.
- 13 Nørgaard BL, Terkelsen CJ, Riiskjaer M, et al. Risk prediction in acute coronary syndrome from serial in-hospital measurements of N-terminal pro-B-type natriuretic peptide. Acute Card Care 2008;10:159-166.
- 14 Dallmeier D, Pencina MJ, Rajman I, et al. Serial measurements of N-terminal pro-brain natriuretic peptide in patients with coronary heart disease. PLoS One 2015;28;10(1):e0117143.
- 15 James SK, Lindahl B, Siegbahn A, et al. NT proBNP and other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients with Unstable Coronary Artery Disease. GUSTO IV Substudy. Circulation 2003;108:275-281.
- 16 Bettencourt P, Azevedo A, Pimenta J, et al. N-Terminal-Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in. Circulation 2004;110(15):2168-2174.
- 17 Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008;16;52(12):997-1003.
- 18 Januzzi JL, Throughton R. Are Serial BNP Measurements Useful in Heart Failure Management? Serial Natriuretic Peptide Measurements Are Useful in Heart Failure Management. Circulation 2013;127:500-508.
- 19 Mair J, Lindahl B, Giannitsis E, et al. Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care? 2016 12. Eur Heart J Acute Cardiovasc Care.
- 20 Zile MR, Claggett BL, Prescott MF, et al. Prognostic Implications of changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol 2016;68:2425-2436.
- 21 De Bold AJ. Atrial Natriuretic Factor: A Hormone Produced by the Heart. Science 1985;230:767-770.
- 22 Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999;134:437-444.
- 23 Clerico A, Passino C, Franzini M, et al. Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chimica Acta 2015;443:17-24.
- 24 De Bold AJ, Boerenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial extracts in rats. Life Sci 1981;28:89-94.
- 25 Epstein M, Loutzenhiser R, Friedland E, et al. Relationship of Increased Plasma Atrial Natriuretic Factor and Renal Sodium Handling During Immersion-induced Central Hypervolemia in Normal Humans. J Clin Invest 1987;79:738-745.
- 26 Eurlings Lw, Sanders-van Wijk S, van Kraaij DJ, et al. Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study. J Card Fail 2014;20(12):881-890.
- 27 Salah K, Kok WE, Eurlings LW, et al. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLaboration on Acute decompensated Heart Failure: ELAN-HF Score. Heart 2014;100(2):115-125.
- 28 Stienen S, Salah K, Dickhoff C, et al. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatment. J Card Fail 2015;21(11):930-934.
- 29 Stienen S, Salah K, Eurlings LW, et al. Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels? Eur J Heart Fail 2015;17(9):936-944.
- 30 Savarese G, Musella F, D'Amore C, et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail 2014;2(2):148-158.
- 31 Sargento L, Satendra M, Longo S, et al. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure. Clin Cardiol. 2013;36(11):677-682.
- 32 Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006;52:1528-1538.
- 33 Packer M, McMurray JJV, Desai Akshay S. et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation 2015;6;131(1):54-61.
- 34 Solomon SD, Zile M, Pieske B. et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-1395.
- 35 Duceppe E, Parlow J, MacDonald P, et al. Canadian cardiovascular society guidelines on perioperative cardiac risk assessment and management for patients undergoing noncardiac surgery. Canadian Journal of Cardiology 2016;10.1016/j.cjca.2016.09.008.
- 36 Colombo A, Cardinale D. Using cardiac biomarkers and treating cardiotoxicity in cancer. Future Cardiol 2013;9(1):105-118. doi:10.2217/fca.12.73.Review.
- 37 Hall PS, Harshman LC, Srinivas S, et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 2013;1:72-78.
- 38 Brune K, Katus HA, Moecks J, et al. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: pilot trial. Clin Chem 2008;54(7):1149-1157.
- 39 Bojunga J, Sarrazin C, Hess G, et al. Elevated plasma levels of Nterminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy. World J Gastroenterol 2006;12(36):5875-5877.
- 40 Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug safety 2006;29(7):567-586.
- 41 Giannitsis E. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. Clin Lab 2005;51(1-2):63-83.
- 42 Häupl T, Burmester GR, Giannitsis E, et al. N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis? Ann Rheum Dis 2007;66(6):838-839.
- 43 European Patent 1577673 assigned to F. Hoffmann-LaRoche AG and Roche Diagnostics GmbH. The use of BNP-type peptides and ANPtype peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload. Patent granted 30.07.2008.







- 44 European Patent 1849009 assigned to F. Hoffmann-LaRoche AG and Roche Diagnostics GmbH. The use of cardiac hormones for assessing the cardiovascular risk with respect to the administration of anti-inflammatory drugs. Patent granted 29.10.2008.
- 45 International patent application WO 2005/124364 assigned to F. Hoffmann-LaRoche AG and Roche Diagnostics GmbH. The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication.
- 46 Natriuretic Peptides Studies Collaboration. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. *Lancet Diabetes Endocrinol.* 2016;4(10):840-849.
- 47 Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. *Eur Heart J* 2003;24,1710-1718.
- 48 Nielsen LS, Svanegaard J, Klitgaard NA, et al. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnea. *Eur J Heart Fail* 2004;6:63-70.
- 49 Al-Barjas M, Nair D, Morris R, et al. How can the role of N terminal pro B Natriuretic Peptide (NT-proBNP) be optimised in heart failure screening? A prospective observational comparative study. *Eur J Heart Fail* 2004;3:51 Supplement 1.
- 50 Gustafsson F, Badskjær J, Hansen F, et al. Value of N-Terminal proBNP in the Diagnosis of Left Ventricular Systolic Dysfunction in Primary Care Patients Referred for Echocardiography. *Heart Drug* 2003;3:141-146.
- 51 Albers S, Mir TS, Haddad M, et al. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. *Clin Chem Lab Med* 2006;44(1):80-85.
- 52 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see <https://usdiagnostics.roche.com> for definition of symbols used):

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume after reconstitution or mixing
	Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2017, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

